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Abstract A molecular model has been developed for human Big 
Endothelin-l, which is the immediate precursor to the potent 
vasoconstrictor polypeptide endothelin-1 and the target of the 
highly specific endothelin converting enzyme. This model is 
produced by a threading algorithm protocol and is consistent with 
all the currently available structural and biochemical data for 
this molecule. 
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I. Introduction 
Human endothelin-1 (ET-1), the most potent vasoconstric- 
tor yet identified, is a 21 amino acid disulphide-crosslinked 
polypeptide [1]; its biosynthesis nvolves a multistep rocess. 
The human ET-1 gene encodes for a 212 amino acid precur- 
sor, preproendothelin [2]. Removal of the signal sequence gen- 
erates proendothelin-1 ( 95 amino acids). This is followed by 
both N-terminal and C-terminal cleavages, which remove 35 
and 122 amino acids, respectively, to release an intermediate 
referred to as Big ET-1 (human form, 38 amino acids). The 
mature and active form of ET-I is formed by an unusual but 
selective hydrolysis of the Trp-21 Val-22 bond of Big ET-1 by 
an endothelin converting enzyme (ECE) [3]. A number of 
structurally homologous i oforms of the endopeptidase called 
ECE-1 have been cloned [4~9]. They are derived from the 
same gene by differential splicing of mRNA transcripts [10]. 
Since Big ET-1 exhibits virtually no activity at any of the 
endothelin receptor sites, this means that molecules which can 
inhibit ECE, preventing the formation of the mature ET-1, 
are potential candidates for therapeutic drug design. To assist 
in the development of specific ECE inhibitors, a knowledge of 
the structure of Big ET-1 is necessary. 
Although the 3-dimensional structure of the mature human 
ET-1 is known from crystallographic studies [11], there is little 
direct evidence for either the structure of Big ET-1 or for the 
structural requirements for specific processing of Big ET-1. 
There is, as yet, no X-ray structure available for Big ET-1. 
NMR [12,13] and circular dichroism (CD) [14] spectroscopic 
studies have concluded that the core residues of Big ET-1 
must adopt similar conformations to those of the correspond- 
ing residues in ET-1. However, because the C-terminus of Big 
ET-1 appears to be relatively flexible, NMR studies have been 
unable provide any information on the structural nature of 
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the C-terminal extension (CTE), i.e. residues 22-38, of Big 
ET-1. The CD studies have suggested qualitatively that the 
CTE contains ome residues in helical and some residues in 
sheet conformations, with perhaps a single additional tight 
turn, but not which residues might be involved in such struc- 
tures [14]. 
A number of biochemical experiments have shed some light 
on the nature of Big ET-1. Incorporation of bulky groups 
onto Lys-9 decreased markedly the vasopressor activity of 
Big ET-1 in vivo even though the same modifications to 
ET-1 had no effect on its hypertensive or in vitro vasocon- 
strictor activity [15]. The rate of conversion of these Lys-9 
modified Big ET-1 molecules by the ECE activities of cultured 
smooth muscle or endothelial cells was substantially reduced. 
A similar decrease in the rate of hydrolysis occurred after 
reduction and S-carboxyamidomethylation of the polypeptide 
to generate a linear Big ET-1 molecule. These experiments led 
to the conclusion that a specific conformation of Big ET-1, 
potentially stabilized by an interaction between the C-terminal 
sequence and Lys-9 or an adjacent amino acid, as well as by 
the presence of one or both of the disulphide bonds, is im- 
portant for the specific hydrolysis of the Trp-21-Val-22 bond 
[15]. 
In this paper, we describe the development of a model for 
Big ET-1 based on the crystal structure of ET-1 using a 
threading algorithm protocol. As will be shown, this model 
is consistent with all the currently available data on the struc- 
ture and function of Big ET-1. Only one other model for Big 
ET-1 has appeared in the literature [16]. It was based on 
homology modeling with scorpion neurotoxin [17], and was 
proposed prior to the availability of the crystal structure of 
ET-1. However, since the ET-1 portion of that earlier Big ET- 
1 model [16] is unlike the now known structure of ET-1, it 
does not fulfil one of the structural requirements for the Big 
ET-1 molecule, and is thus unlikely to represent the structure 
of the actual molecule. 
2. Materials and methods 
2.1. Modeling procedure 
The 212 residue sequence ofhuman preproendothelin was threaded 
through all the known 3-dimensional structures ofproteins held in the 
Brookhaven Protein Data Base up to January 1995 using the 
THREADER algorithm developed by Jones et al. [18-20]. The opti- 
mum aligned structure identified was 1 gdh (d-glycerate d hydrogenase 
- apo form) [21]. The Epair value was -3.85, indicating a good 
alignment. Cys-53 to Val-74 of preproendothelin (equivalent to Cys- 
1 to Val-22 of Big ET-1) align with Lys-147 to Phe-168 of lgdh; Asn- 
75 to Pro-77 (Asn-23 to Pro-25 in Big ET-1) form an insertion, and 
finally Glu-78 to Ser-90 (Glu-26 to Ser-38 in Big ET-1) align with 
Asp-169 to Ser-181 in lgdh. 
This procedure primarily provides a guide to the backbone confor- 
mation, without any requirement for corresponding sequence similar- 
ities. Flexibility observed in the threading procedure allowed replace- 
ment of the regular helix in lgdh with the irregular helix (residues 10~ 
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Fig. 1. Stereo view of the model of Big ET-1. The red coil traces the path of the polypeptide. Hydrogen bonds are shown in yellow. 
20) of ET-1. Using the molecular modeling package SYBYL [22], ET- 
1 was fitted into the thread using its beta-strand as the target. The 
residues of lgdh were mutated to correspond to the Big ET-1 se- 
quence. The model was then minimized using the Kollman all atom 
force field and Gateiger-Marsili partial charge parameters in SYBYL. 
Dynamic analyses at 300 K indicated conformational flexibility of the 
region between Pro-30 and Ser-38. To examine the allowed conforma- 
tions about the flexible Pro-30-Tyr-31 bond, a 360 ° psi torsion rota- 
tion of Tyr-31 at 5 ° intervals with minimization was undertaken, 
which indicated a strongly favourable lectrostatic interaction when 
Ser-38 came into close proximity to Lys-9. The final model was the 
result of 1000 iterations of the minimization procedure. 
2.2. Analyses of the model 
The stereochemical quality of the model was evaluated using the 
PROCHECK software [23]. Analyses of the model including determi- 
nations of surface area, secondary structure, hydrogen bonds, etc. 
were performed using the CCP4 suite of programs (SERC Collabora- 
tive Computer Project N. 4, Daresbury Laboratory, UK). Graphics 
displays utilized PREPI [24] and SETOR software [25]. 
~,~'~ i ! i~  ~ 
Fig. 2. Ribbon diagrams comparing the crystal structure of ET-1 [10] with the model for Big ET-1 (this work). The disulphide bonds are shown 
in yellow. 
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3. Results 
3.1. Rationale for the method used 
Big ET-1 is a relatively small polypeptide and hence we 
considered the conventional sequence homology modeling 
schemes used for larger proteins unlikely to be applicable in 
this case. Whilst we were able to find some fragments of 
structures in the Brookhaven Protein Data Base with modest 
homology to the CTE, there were none which exhibited suffi- 
cient overlap with the C-terminal part of ET-I  to provide 
information on how the CTE would attach onto and interact 
with the remainder of the molecule in three dimensions. 
Hence, we needed a method that would effectively model 
the whole of Big ET-1 rather than its parts, while at the 
same time being consistent with the known (ET-1) part of 
the structure. 
Another consideration for the type of modeling utilized was 
that ET-1, and ultimately Big ET-1, are biosynthesized as a 
larger precursor, and it may be that the presence of the entire 
precursor protein is necessary to fold Big ET-1 efficiently into 
its correct structure. Therefore, we decided to test a threading 
algorithm [18] strategy to examine whether we could find a 
Table 1 
Surface accessibilities of ET-1 and Big ET-I structures (expressed as 
fractions of the maximal surface accessible area for each type of 
residue) 
Residue ET-1 Big ET-1 
Cys-I 0.89 0.45 
Ser-2 0.96 0.74 
Cys-3 0.59 0.03 
Ser-4 0.19 0.23 
Ser-5 0.79 0.01 
Leu-6 0.95 0.73 
Met-7 0.62 0.80 
Asp-8 0.89 0.47 
Lys-9 0.84 0.45 
Glu- 10 0.52 0.42 
Cys- 11 0.02 0.04 
Val-12 0.26 0.38 
Tyr-13 0.84 0.83 
Phe-14 0.42 0.41 
Cys-15 0.10 0.02 
His-16 0.52 0.45 
Leu-17 0.51 0.44 
Asp-18 0.86 0.39 
lle-19 0.68 0.31 
Ile-20 0.55 0.59 
Trp-21 0.93 0.61 
Val-22 0.65 
Asn-23 0.84 
Thr-24 0.37 
Pro-25 0.67 
Glu-26 0.34 
His-27 0.63 
Val-28 0.60 
Val-29 0.55 
Pro-30 0.42 
Tyr-31 0.91 
Gly-32 0.68 
Leu-33 0.55 
Gly-34 0.27 
Ser-35 0.70 
Pro-36 0.90 
Arg-37 1.00 
Ser-38 0.67 
Fig. 3. Model of Big ET-1 showing the residues adjacent o the 
bonds cleaved by proteases (2122 and 31-32) in red and those ad- 
jacent to bonds cleaved in ET-1 but not Big ET-1 (5-6, 16-17, and 
18 19) in green. 
favourable fold for the whole precursor molecule, and then 
extract the folded Big ET-1 structure from the context of the 
larger molecule. 
An essential criterion for success was that the secondary 
structures of the ET-1 portion of the aligned structure must 
contain the same types of secondary structures found in the 
ET-1 crystal structure. The threading strategy was successful 
in that it found an optimum aligned structure with a low 
Epair and in which, most importantly, the helix and beta- 
strand alignments matched the equivalent structures in ET- 
1. The final model produced is shown in Fig. 1. 
3.2. General description of  the model 
ET-1 consists of an N-terminal beta-strand linked by a loop 
region to a long irregular helix that extends from residue 10 to 
residue 20 near the C-terminal end of the molecule [11]. The 
molecule is cross-linked via two disulphide bonds between 
residues 1 and 15 and 3 and 11, respectively (Fig. 2). The 
structure of the endothelin core in the Big ET-1 model is 
essentially the same as in the ET-1 crystal structure, with 
the exception that the C-terminal helix is extended by 3 resi- 
dues to Asn-23 in Big ET-1. Additionally, the CTE contains a 
hydrogen-bonded loop (between residues 18 and 24) that 
causes the chain to fold back on itself, creating a parallel 
beta-sheet that is hydrogen-bonded between residues 1 and 5 
of the first strand and between residues 27 and 29 of the 
second strand, thereby producing a relatively compact struc- 
ture. Finally, amino acids 35 and 38 in the C-terminus form a 
hydrogen-bonded tight turn which brings the side chain of 
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residue Ser-38 back to form a hydrogen-bonded contact with 
the side chain of residue Lys-9. Consequently, the Big ET-1 
model is a globular structure. 
The surface accessibilities (Table 1) of residues 1 5, which 
form one strand of the beta-sheet present in Big ET-1, are 
greatly reduced relative to their counterparts in ET-1. The 
surface accessibilities of residues at the beginning of the heli- 
cal region (Glu-10-Cys-15) are essentially unchanged in Big 
ET-1 relative to ET-1, while those residues that form the C- 
terminal end of ET-1 are less accessible in Big ET-1 due to the 
presence of the loop in the CTE which folds back on residues 
16-21 in Big ET-1. One other notable difference in Big ET-1 is 
the reduced accessibility of residue 9, whose side chain hydro- 
gen bonds with the side chain of residue 38 in the CTE. 
4. Discussion 
The most important test of any molecular model is whether 
it is consistent with all the experimental data, both structural 
and biochemical, available for that molecule. 
NMR studies [12,13] have shown that the conformations of 
residues 1-16 of Big ET-1 are very similar to those of the 
same residues in ET-1. However, the NMR studies have 
been unable to define accurately a structure for the part of 
the Big ET-1 molecule beyond residue 16, so the nature of the 
all-important C-terminal extension remains unknown. Thus, 
as our modeling only effectively changed the conformation of
the last two residues (20 and 21) in ET-1, it is entirely con- 
sistent with the available NMR data. 
Like the NMR studies, the only CD spectroscopic data for 
Big ET-1 also suggested that its core residues have very simi- 
lar conformations to those in ET-1 [14]. That study concluded 
that it was difficult to quantitate the secondary structure for 
such a small flexible polypeptide, but estimated that the C- 
terminal extension would contain some additional residues in 
helical and sheet conformations and an additional turn-type 
structure. Residues 21-23 of the Big ET-1 model fulfil the 
additional helical content requirement, and residues 27 29 
provide the additional sheet component, with the hydrogen- 
bonded turn between residues 35 and 38 producing the new 
turn component. Thus, this model is compatible with all the 
(albeit rather qualitative) information available on the second- 
ary structure of Big ET-1. 
While the spectroscopic studies have provided only a lim- 
ited amount of structural information against which the mod- 
el can be tested, there is some very specific experimental in- 
formation available on the Big ET-1 structure from 
proteolysis tudies, which has important implications for the 
structure. Firstly, the site of cleavage by ECE is between 
residues 21 and 22, so it is expected that these residues hould 
have a high degree of surface accessibility to enable interac- 
tion with the protease. ECE is highly specific for the Trp Val 
bond, so the side chains for those residues hould be surface 
exposed. Indeed, these residues are more than 50% surface 
accessible, and the peptide bond itself is exposed in the Big 
ET-1 molecule, so cleavage by ECE would be expected (Fig. 
3). Cleavage of Big ET-1 between bonds 31 and 32 by several 
other proteases has also been reported [26-28], so it is antici- 
pated that these residues hould also exhibit significant surface 
exposure. In the model, they do indeed have a surface acces- 
sibility of greater than 50%, again consistent with this being a 
potential cleavage site. 
Lack of cleavage can also provide information on inacces- 
sible sites in a molecule which can be useful in evaluating a 
structure, especially if there is evidence for cleavage of a re- 
lated molecule by the same enzyme (Fig. 3). Bonds that are 
cleaved by various proteases in ET-I but not Big ET-1, in- 
clude Ser-5 Leu-6, His-16-Leu-17, and Asp-18-Ile-19 [29-32]. 
In all these cases, at least one residue of the pair is less than 
50% exposed in Big ET-1, and also in all cases, there is a 
notable reduction in accessibilities from those in ET-1 (where 
all residues are > 50% exposed). This is precisely the type of 
structure that would be expected in a correct model of Big 
ET-1. 
Likewise, because Big ET-1 exhibits essentially no activity 
at any of the endothelin receptors, one would anticipate that 
its structure should reflect a decrease in accessibility relative to 
ET-1 for at least one of the residues primarily involved in the 
interactions with its receptors. A wide range of structure-ac- 
tivity relationship studies point to the residues on one face of 
the helix, notably 10, 14, 18, and 21 as being involved in the 
binding interaction [33]. Whilst residues 10 and 14 are only 
slightly altered in their accessibilities in Big ET-1, residues 18 
and 21 have substantially reduced accessibilities, indicating 
the model is also consistent with these data. 
The studies which showed that chemical modification of 
Lys-9 in Big ET-1 decreased the vasopressor activity in vivo, 
whilst the same modifications to ET-1 did not affect its activ- 
ity, suggest hat the conformation of Big ET-1 is altered by 
this modification in a way that makes it less susceptible to 
proteolysis by ECE [15]. This would be expected for the model 
proposed since Lys-9 is involved in a conformational-stabiliz- 
ing side chain hydrogen bond that could not be present in a 
Lys-9-modified molecule. Hence, while the Lys-9 side chain is 
not apparently essential for interactions or activity of the 
mature ET-1, it does appear necessary for maintaining a pro- 
teolytically competent form of Big ET-1. 
Finally, it has been observed that the cross-reactivity of Big 
ET-1 to antibodies produced against residues 1 15 of ET-1 is 
decreased relative to ET-1, suggesting that Big ET-1 must be a 
globular molecule with a CTE that blocks antibody accessi- 
bility to some of these amino terminal residues [15]. That is 
certainly true for the present model, where residues 1-5 and 8 
and 9 are considerably more buried in the Big ET-1 structure 
than in the ET-1 structure. 
In summary, we have developed a model for Big ET-1, the 
immediate precursor to ET-I, which is normally cleaved in 
vivo by the endothelin converting enzyme. While there is little 
direct structural information available on Big ET-1, there is a 
large amount of biochemical data against which any model of 
Big ET-I must be tested. The model we have presented in this 
paper is stereochemically reasonable and consistent with all 
the structural and biochemical information currently available 
on this molecule. While a model such as this will obviously 
not be fully correct in all its details, it may serve a useful 
purpose for the development of further experiments and the 
design of new molecules which may act as inhibitors of ECE 
and thus provide the basis for useful therapeutic develop- 
ments. 
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